News >

Frontline Alectinib Approved in Europe for ALK-Positive NSCLC

Jason M. Broderick @jasoncology
Published: Friday, Dec 22, 2017

Dr. Sandra Horning

Sandra Horning, MD
The European Commission (EC) has approved alectinib (Alecensa) for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor.

-positive NSCLC in the United States, Japan, and Turkey.
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer. Roche. Available at: Accessed December 22, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication